3 high dividend yield stocks to watch

A high dividend yield can be an attractive opportunity for investors seeking passive income. However, not every high yield stock is stable and safe. It is important to distinguish between those that can offer long-term growth and stability and those that present risk. In November, analysts' attention is focused on several companies that not only have high dividend yields, but also a solid foundation for future growth.

If you're looking for investment opportunities that combine attractive dividends with the potential for growth, the following stocks might interest you. Here are three companies that are currently appearing in analyst recommendations.

AbbVie $ABBV

AbbVie is a pharmaceutical company with a stable dividend and solid long-term prospects. Its dividend yield of 3.2% is above average, and analysts expect it to continue to grow. In November, AbbVie raised its quarterly dividend by 5.8%. While the company faces challenges, such as declining sales of Humira, its strong and diversified portfolio allows it to maintain positive growth.

AbbVie has made several strategic acquisitions in the past few years, which has helped it expand its product offerings and ensures revenue stability. In addition, its investments in new medicines are expected to continue to contribute to growth.

Gilead Sciences $GILD

Gilead Sciences offers a dividend yield of over 3.4%, which is well above average. The company is known for its stable dividend policy, having increased dividends by over 20% in recent years. Despite some hurdles such as regulatory issues and pandemic challenges, Gilead has been able to maintain stable earnings, largely due to its strong position in the HIV drug market.

Currently, Gilead is focused on growth in oncology, where it has several promising programs in clinical development. The company is also investing in new therapies in other areas, which helps it maintain long-term growth and dividend stability.

Pfizer $PFE

Pfizer is known for its strong position in vaccines, but it also offers an attractive dividend yield of 6.2%. This yield, along with the stock's low valuation, makes Pfizer an interesting choice for investors looking for dividend opportunities. Despite patent expirations on some key products, the company is still focused on growth through new product and vaccine development.

Pfizer has a strong pipeline, including drugs for migraine, eczema and alopecia, and analysts believe its development in respiratory viruses and new vaccines will deliver long-term growth.

Disclaimer: There is a lot of inspiration to be found on Bulios, but stock selection and portfolio construction is up to you, so always do a thorough analysis of your own.

Source.